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chronic GvHD; one with Etanercept, Cyclosporine and Sol-
umedrol and one with Orapred and Imuran. One patient was
still on prophylactic Tacrolimus when hyperthyroidism was
diagnosed 9 months after transplant. All patients required a
form of ablative therapy. Two received radioactive iodine as
treatment. Three patients received Methimazole alone. One
patient failed Methimazole, received radioactive iodine and
then underwent thyroidectomy revealing follicular carci-
noma. One of the patients did not receive any therapy; he
had Hoshimoto’s thyroidits and went on to develop hypo-
thyroidism. Another patient had a total thyroidectomy that
revealed diffuse hyperplasia. All patients are surviving 1 to 9
years after diagnosis of thyroid disease.Table 1
LV Dysfunction
at day +100
(n[23)
No LV
Dysfunction
at day +100
(n[69)
p
value
Male 14 (61%) 47 (68%) 0.61
Mean Age in Yrs (95% CI) 9.6 (6.3-12.9) 6.9 (5.5-8.2) 0.068
Diagnosis 0.36
Malignancy 12 (51%) 22 (32%)
Immune deﬁciency 5 (21%) 29 (42%)
Bone Marrow Failure 5 (21%) 15 (22%)
Genetic/Metabolic 1 (7%) 2 (3%)
Benign Hematology 0 1 (1%)
Therapy / Conditioning
Previous anthracycline 11 (48%) 18 (26%) 0.070
RIC 12 (52%) 42 (61%) 0.47
Myeloablative 11 (48%) 27 (39%)
Donor 0.11
Autologous 7 (30%) 9 (13%)
Allogeneic 16 (70%) 60 (87%)
Source 0.032
Bone Marrow 11 (48%) 43 (62%)
Cord 0 8 (12%)
PBSC 12 (52%) 18 (26%)
Type 0.14
Auto 7 (30%) 9 (13%)
Related Donor 3 (13%) 8 (12%)
Unrelated Donor 13 (57%) 52 (75%)
Transplant Complications
GVHD 5 (22%) 26 (38%) 0.21
Engraftment Syndrome 1 (4%) 11 (16%) 0.28
Adenovirus 4 (17%) 12 (17%) 1.00
CMV 3 (13%) 19 (28%) 0.26
EBV 7 (30%) 31 (45%) 0.33
Death at 1 year 5 (22%) 14 (20%) 1.00286
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Background: Neuroblastoma (NB) is a pediatric tumor of
neural crest origin. It is one of several small round blue cell
tumors. Patients who have MYC-N ampliﬁed tumors that
respond sub-optimally to initial therapies have poor out-
comes with 30-40% long-term survival. These tumors may
have a higher content of therapy resistant cancer stem cells
that utilize autophagy as an enhanced survival mechanism.
In the following study we identiﬁed a stem cell phenotype in
an MYC-N ampliﬁed neuroblastoma cell line from ATCC (BE-
2) and investigated the activity of two new classes of drugs
(GLUT-1 inhibitors and bisquinolone antimalarials).
Methods: Flow cytometry was utilized to identify stem cell
fractions within an unselected BE-2 population. Brieﬂy, in
side population analysis 1 x 106 cells were incubated with
Hoescht IMDM staining media (1 mcg/ml) and incubated for
30 minutes with Hoechst 33342 dye. Cells were then kept on
ice until ﬂow cytometry analysis. Flow cytometry was per-
formed using a BD FACSAria. Autophagy was measured using
a ﬂow cytometry based assay measuring membrane bound
LC3 (Milipore Inc). Screening assays for drug activity used a
96 well platform with MTT to measure cytotoxicity of bis-
quinolone and GLUT-1 cytotoxicity. Neurospheres were
grown in non-adherent plates to assess activity in this stem
cell enriched screening assay.
Results: Flow cytometry demonstrated a high percent of side
population cells on three separate analyses (11%, 38%, 28% of
live cells). In comparison twomurine breast cancer cells lines
(Clone 66 and 4T1) and human mantle cell line (Granta) side
population fractions were approximately 1% of live cells. A
commercially available bisquinolone, hydroxychloroquine,
demonstrated the ability to inhibit autophagy as measured
by the ﬂow cytometry assay. Using the two in-vitro screening
assays described above, a number of bisquinolone antima-
larials and GLUT-1 inhibitors were assessed for activity and
three compounds were identiﬁed with high activity (Q2-15
antimalarial and STF-04 and STF-05 GLUT-1 inhibitor).
Conclusion: In the following study we describe a large
cancer stem cell population as measured by side population
assay in BE-2 human neuroblastoma cells. Bisquinolone
antimalarial drugs demonstrated the ability to inhibit auto-
phagy. Both bisquinolone antimalarials and GLUT-1inhibitors demonstrated cytotoxic activity in an MTT assay
and activity in a stem cell enriched neurosphere assay. These
two classes of drugs have the potential to improve therapy in
poor prognostic neuroblastoma and studies combining
candidate compounds are ongoing both in cell culture and an
NSG animal model.
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Background: Cardiac evaluation during ﬁrst 100 days after
stem cell transplant (SCT) is usually performed only if clini-
cally indicated, however, patients with mild left ventricular
(LV) dysfunction can be asymptomatic. Scheduled post-SCT
screening at day 100 may identify patients with subacute
cardiac toxicity identiﬁed as LV dysfunction.
Methods:We conducted a single center prospective study to
screen for LV dysfunction after SCT in 100 consecutive pa-
tients. Patients received echocardiography screening prior to
SCT and 100 days post-SCT. Patients were classiﬁed as having
LV dysfunction if echocardiography met at least one of the
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fractional shortening (FS) two standard deviations below the
age adjusted mean (3) >10% decrease in EF or FS at day 100
from baseline.
Results: 92 of 100 consecutive patients completed day 100
screening (8 died). 25% (23 of 92) had LV dysfunction at day
100 (Table). 96%(22 of 23) were asymptomatic at time of
screening. Patients with LV dysfunction were older at the
time of SCT than those without (p¼0.068). Patients receiving
PBSC grafts had an increased incidence of LV dysfunction (p¼
0.032), likely related to the diagnosis of those patients (ma-
lignancy receiving autologous SCT and Fanconi Anemia).
Overall, however, diagnosis was not signiﬁcantly associated
with LV dysfunction. Patients with previous anthracycline
exposure had increased LV dysfunction compared to those
without (48% vs. 26%). GVHD, engraftment syndrome, and
viremias in the ﬁrst 100 days were not signiﬁcantly associ-
ated with decreased RV function. Death at 1 year was similar
in both groups.
Discussion: 25% of patients showed signs of cardiac
dysfunction at day 100, which was higher than anticipated.
Although there were no acute differences in outcome, the
long-term complications are unknown. Echocardiography at
day 100 identiﬁes SCT cardiac dysfunction, however, more
research is needed to understand the overall impact on long-
term outcome.288
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Background: Sleep disruption can adversely affect meta-
bolism, psychological well-being, performance, inﬂamma-
tory cytokines, immune function, and cardiac function and is
likely overlooked as a side effect of stem cell transplantation
(SCT). There are no objective studies evaluating sleep in pe-
diatric SCT patients. Actigraphic monitoring utilizes a small
monitor that is worn like a wristwatch and when used in
combination with self-reports of bedtime and rising time,
has been found to be a reliable and valid measure of sleep
patterns.
Purpose: To evaluate sleep patterns in SCT children and
young adults through actigraphy, sleep diaries, and evalua-
tion of environmental factors that inﬂuence sleep disruption.
Methods: Objective sleep parameters were measured with
the Micro-Motionlogger SleepWatch (Ambulatory Moni-
toring, Inc.) actigraph which was worn continuously. Sleep-
wake patterns were reported in a sleep diary to allow for
screening of artifacts (e.g., actigraph removal). The number ofwaking episodes per cycle of sleep, duration of sleep, mi-
nutes of sleep, and sleep efﬁciency (Abnormal is< 90%) were
calculated using actigraphy data. Room entry checklists were
utilized to record the frequency of nocturnal room entries in
a separate cohort of patients on randomly-selected nights on
the BMT unit.
Results:We obtained 71 nights of sleep for eight patients. Six
patients (75%) were male with a median age of 12.4 years
(IQR 10.6-14.1) at time of actigraphy. Thirty-six nights (51%)
were pretransplant, 35 nights (49%) were post-transplant.
The average sleep onset time was midnight with an average
rise time of 9:00 am. The median duration from onset to
offset was 9.1 hours (IQR 8.0-10.2) with a median duration of
7.1 hours (IQR 6.1-7.8). The median number of waking epi-
sodes per sleep cycle was 12 (IQR 9-17). Median sleep efﬁ-
cacy was 80.7% (IQR 70 to 89%); sleep efﬁciency was
abnormally low 75% of the nights. During 189 nights of room
monitoring, patient’s rooms were entered a median of 12
times per night (IQR 10-15).
Conclusions: These preliminary data suggest that pediatric
patients undergoing SCT often have poor sleep quality while
hospitalized. Frequent room entries, amongst other causes,
may contribute to sleep disruption. Further research is
needed to fully understand the impact of sleep disruption
after HSCT, and evaluate potential interventions to improve
sleep quality.289
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Background: In 2013, the Centers for Disease Control and
Prevention developed a modiﬁcation of blood stream infec-
tion (BSI) deﬁnition, termed mucosal barrier injury labora-
tory-conﬁrmed bloodstream infection (MBI-LCBI). In January
of 2013, the National Healthcare Safety Network (NHSN)
integrated a MBI-LCBI deﬁnition into the methods for BSI
surveillance to aid in identiﬁcation of BSIs reported as central
line associated blood stream infections (CLABSI) likely
related to mucosal barrier injury. There is little literature
describing the timing, patients at risk, and incidence of MBI-
LCBIs in comparison to CLABSIs and BSIs from a secondary
source (secondary BSIs).
